John Leung1, Raman Mehrzad2, Navneet Virk Hundal3, Alexandra Alejos2, Paul E Hesterberg2, Aubrey J Katz4, Qian Yuan4, Wayne G Shreffler5. 1. Food Allergy Center, Massachusetts General Hospital, Boston, Mass; Center of Immunology and Inflammatory Disease, Massachusetts General Hospital, Boston, Mass; Food Allergy Center at Tufts Medical Center and Floating Hospital, Boston, Mass. 2. Food Allergy Center, Massachusetts General Hospital, Boston, Mass. 3. Food Allergy Center, Massachusetts General Hospital, Boston, Mass; Center of Immunology and Inflammatory Disease, Massachusetts General Hospital, Boston, Mass. 4. Food Allergy Center, Massachusetts General Hospital, Boston, Mass; Pediatric Gastroenterology, MassGeneral Hospital for Children, Boston, Mass. 5. Food Allergy Center, Massachusetts General Hospital, Boston, Mass; Center of Immunology and Inflammatory Disease, Massachusetts General Hospital, Boston, Mass. Electronic address: wshreffler@mgh.harvard.edu.
Abstract
BACKGROUND: One half to one third of the patients with eosinophilic esophagitis (EoE) do not achieve histological remission on initial treatment. We wondered whether these treatment failure patients are a distinct clinical subset. OBJECTIVE: To analyze EoE treatment outcomes in a predominantly pediatric population. METHODS: We reviewed 100 serial EoE cases at Massachusetts General Hospital starting from 2007. We defined histological remission as peak esophageal eosinophil count of less than 10/hpf. RESULTS: Ninety-seven patients with EoE underwent initial treatments: 54 of 81 (67%) responded to dietary therapy, and 9 of 16 (56%) responded to topical glucocorticoids. Of the 34 who failed initial treatment, 24 underwent various second treatment regimens and 54% (13 of 24) responded. Eight of the remaining 11 who failed second treatment underwent additional treatments and 2 ultimately responded. The overall response rate by intent-to-treat analysis increased from 65% (63 of 97) with initial treatment to 78% (76 of 97) with rescue treatment, and further to 80% (78 of 97) with multiple treatments. On a per-protocol basis, the overall response rate was 93% (78 of 84); however, patients who failed the first 2 rounds of therapy had only a 20% response rate. Patients who responded to initial treatment were found to have more symptoms and endoscopic abnormalities. Comparison of patients who failed both initial and rescue therapy with those who responded to rescue therapy did not identify any differentiating clinical features. CONCLUSIONS: More than half of the patients who failed initial EoE treatment could still achieve histological remission with individualized rescue treatments. No clinical features could predict response to rescue treatment.
BACKGROUND: One half to one third of the patients with eosinophilic esophagitis (EoE) do not achieve histological remission on initial treatment. We wondered whether these treatment failurepatients are a distinct clinical subset. OBJECTIVE: To analyze EoE treatment outcomes in a predominantly pediatric population. METHODS: We reviewed 100 serial EoE cases at Massachusetts General Hospital starting from 2007. We defined histological remission as peak esophageal eosinophil count of less than 10/hpf. RESULTS: Ninety-seven patients with EoE underwent initial treatments: 54 of 81 (67%) responded to dietary therapy, and 9 of 16 (56%) responded to topical glucocorticoids. Of the 34 who failed initial treatment, 24 underwent various second treatment regimens and 54% (13 of 24) responded. Eight of the remaining 11 who failed second treatment underwent additional treatments and 2 ultimately responded. The overall response rate by intent-to-treat analysis increased from 65% (63 of 97) with initial treatment to 78% (76 of 97) with rescue treatment, and further to 80% (78 of 97) with multiple treatments. On a per-protocol basis, the overall response rate was 93% (78 of 84); however, patients who failed the first 2 rounds of therapy had only a 20% response rate. Patients who responded to initial treatment were found to have more symptoms and endoscopic abnormalities. Comparison of patients who failed both initial and rescue therapy with those who responded to rescue therapy did not identify any differentiating clinical features. CONCLUSIONS: More than half of the patients who failed initial EoE treatment could still achieve histological remission with individualized rescue treatments. No clinical features could predict response to rescue treatment.
Authors: Amir F Kagalwalla; Timothy A Sentongo; Sally Ritz; Therese Hess; Suzanne P Nelson; Karan M Emerick; Hector Melin-Aldana; B U K Li Journal: Clin Gastroenterol Hepatol Date: 2006-07-21 Impact factor: 11.382
Authors: Chris A Liacouras; Jonathan M Spergel; Eduardo Ruchelli; Ritu Verma; Maria Mascarenhas; Edisio Semeao; Jonathan Flick; Janice Kelly; Terry Brown-Whitehorn; Petar Mamula; Jonathan E Markowitz Journal: Clin Gastroenterol Hepatol Date: 2005-12 Impact factor: 11.382
Authors: Carol J Henderson; J Pablo Abonia; Eileen C King; Philip E Putnam; Margaret H Collins; James P Franciosi; Marc E Rothenberg Journal: J Allergy Clin Immunol Date: 2012-04-26 Impact factor: 10.793
Authors: Evan S Dellon; Nirmala Gonsalves; Ikuo Hirano; Glenn T Furuta; Chris A Liacouras; David A Katzka Journal: Am J Gastroenterol Date: 2013-04-09 Impact factor: 10.864
Authors: John Leung; Navneet Virk Hundal; Aubrey J Katz; Wayne G Shreffler; Qian Yuan; Carolyn A Butterworth; Paul E Hesterberg Journal: J Allergy Clin Immunol Date: 2013-09-29 Impact factor: 10.793
Authors: Matthew A Rank; Rajiv N Sharaf; Glenn T Furuta; Seema S Aceves; Matthew Greenhawt; Jonathan M Spergel; Yngve T Falck-Ytter; Evan S Dellon Journal: Ann Allergy Asthma Immunol Date: 2020-05 Impact factor: 6.347
Authors: Matthew A Rank; Rajiv N Sharaf; Glenn T Furuta; Seema S Aceves; Matthew Greenhawt; Jonathan M Spergel; Yngve T Falck-Ytter; Evan S Dellon Journal: Gastroenterology Date: 2020-05 Impact factor: 33.883
Authors: Anne C A Mudde; Willem S Lexmond; Richard S Blumberg; Samuel Nurko; Edda Fiebiger Journal: World Allergy Organ J Date: 2016-07-15 Impact factor: 4.084
Authors: Liselot De Vlieger; Lieselot Smolders; Lisa Nuyttens; Sophie Verelst; Christine Breynaert; Tim Vanuytsel; Ilse Hoffman; Dominique Ma Bullens Journal: Front Immunol Date: 2021-05-19 Impact factor: 7.561